CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Hiring the Right CRO to Improve Clinical Trial Outcomes

Hiring the Right CRO to Improve...

 Altasciences Receives Accreditation From College Of American Pathologists

Altasciences Receives Accreditation...

Life Science Marketing: Content Distribution for Businesses

Life Science Marketing: Content...

Protypia, Inc.'S Acquisition By Inotiv, Inc. Broadens The Company's Protein/Peptide Bioanalytical Capabilities

Protypia, Inc.'S Acquisition By...

Making the Most of Contract Research Organization Relationships

Making the Most of Contract Research...

How Cloudbased Lims Helps Cros

How Cloudbased Lims Helps Cros

MMS Holdings Announces New Pro-Bono Support Program

MMS Holdings Announces New Pro-Bono...

Inotiv Secures MilliporeSigmas BioReliance Genetic Toxicology Assets

Inotiv Secures MilliporeSigmas...

Hiring the Right CRO to Improve Clinical Trial Outcomes

Hiring the Right CRO to Improve...

 Altasciences Receives Accreditation From College Of American Pathologists

Altasciences Receives Accreditation...

Life Science Marketing: Content Distribution for Businesses

Life Science Marketing: Content...

Protypia, Inc.'S Acquisition By Inotiv, Inc. Broadens The Company's Protein/Peptide Bioanalytical Capabilities

Protypia, Inc.'S Acquisition By...

Making the Most of Contract Research Organization Relationships

Making the Most of Contract Research...

How Cloudbased Lims Helps Cros

How Cloudbased Lims Helps Cros

MMS Holdings Announces New Pro-Bono Support Program

MMS Holdings Announces New Pro-Bono...

Inotiv Secures MilliporeSigmas BioReliance Genetic Toxicology Assets

Inotiv Secures MilliporeSigmas...

Pacira BioSciences Declares Top-line Results from Phase 3 STRIDE Study Evaluating EXPAREL as a Lower Extremity Nerve Block

Life Sciences Review Life Sciences Review | Thursday, June 03, 2021
Tweet

Pain and total opioid use are significantly lowered by EXPAREL from 24 to 96 hours, compared to the bupivacaine HCl (p<0,01).


FREMONT, CA:  Pacira BioSciences, Inc., the industry leader in its commitment to non-opioid pain management and regenerative health solutions, publish topline results from its Phase 3, randomized, double-blinded, active-controlled, multicenter STRIDE study.


EXPAREL administers as combined sciatic (in popliteal fossa) and saphenous (in adductor canal). Under the curve versus bupivacaine HCl, nerve blocks do not show statistical significance for the study’s primary endpoint of reducing cumulative pain scores from 0 to 96 hours as measured by the area. EXPAREL achieves statistical significance versus bupivacaine HCl for secondary endpoints of reducing cumulative pain scores from 24 to 96 hours post-surgery (p<0.001) and total opioid consumption from 24 to 96 hours post-surgery (p<0.01). EXPAREL also attains statistical significance versus bupivacaine HCl for the area under the curve cumulative pain scores from 12 to 96 hours (p<0.02). The EXPAREL group achieves and maintains mild pain at 36 hours (Least Square Mean NRS 3.0), while bupivacaine HCl is moderate (Least Square Mean NRS 4.7).


There are no clinically relevant safety issues observed in STRIDE, specifically no reports of falls and no serious adverse events observed in the study.


 


STRIDE offers essential insights into the critical position of EXPAREL as the cornerstone of multimodal protocols to achieve both early-onset and prolonged pain management goals. The company will complete a full analysis of the STRIDE study and plans to discuss these highly informative data and next steps with the U.S. Food and Drug Administration (FDA). Pacira intends to submit the full results from the Phase 3 STRIDE study for presentation at future scientific conferences and publication in a peer-reviewed journal.


“In the absence of preoperative multimodal therapy, the study demonstrated the advantages of EXPAREL versus bupivacaine from 24 hours and beyond. The findings from this study are valuable and demonstrate the ability of an EXPAREL long-acting lower extremity nerve block to provide significant pain relief that extends to 96 hours. These data also add to the significant body of evidence supporting the excellent safety profile of EXPAREL, says Dave Stack, chairman and chief executive officer of Pacira BioSciences. The market is in need of additional approaches to safe and effective opioid-sparing pain management as the surgical suite remains a key gateway to opioid misuse and abuse. We look forward to discussing these important findings with FDA and defining the next steps for broadening the EXPAREL label to include lower extremity nerve blocks.”


Weekly Brief

loading
Top 10 Preeminent Cros – 2022
> <
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue

Read Also

Prophesying DNA Sequencing for 2023

Crucial Workflows of Next-Generation Sequencing

An Overview of Next-Generation Sequencing

The Role of AI in Accurate Medical Writing

Patrik Renblad to Join Cantargia as Chief Financial Officer

Overview of the Life Sciences BPO Market

Dr. Zamaneh Mikhak Joins TFF Pharmaceutical as the New Chief Medical Officer

The Significance of AI in Medical Writing

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/pacira-biosciences-declares-topline-results-from-phase-3-stride-study-evaluating-exparel-as-a-lower-extremity-nerve-block--nwid-385.html